{"id":"W4415442914","doi":"10.1182/bloodadvances.2025017731","title":"Efficacy and safety of vemircopan as monotherapy in patients with paroxysmal nocturnal hemoglobinuria","year":2025,"lang":"en","type":"article","venue":"Blood Advances","topic":"Complement system in diseases","field":"Immunology and Microbiology","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Université Laval; Centre intégré de santé et de services sociaux de Chaudière-Appalaches; Centre Intégré de Santé et Services Sociaux de Chaudière-Appalache; University of Toronto","funders":"Janssen Pharmaceuticals; Samsung; Novo Nordisk; Agios Pharmaceuticals; Swedish Orphan Biovitrum; Apellis Pharmaceuticals; Omeros Corporation; BioCryst; Regeneron Pharmaceuticals; BeiGene; Sanofi; Celgene; AstraZeneca; Alexion Pharmaceuticals; Pfizer; Amgen","keywords":"Paroxysmal nocturnal hemoglobinuria; Eculizumab; Adverse effect; Clinical endpoint; Hemoglobinuria; Clinical trial; Anemia; Hemolysis","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0007630152,0.0003527221,0.001015008,0.0001655339,0.0002639631,0.0005061306,0.0003300243,0.0006220295,0.00198437],"category_scores_gemma":[0.000807962,0.0001567643,0.0004709528,0.0001437839,0.0002018134,0.0003902402,0.0001564971,0.001036961,0.0003081535],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005009849,"about_ca_system_score_gemma":0.00056176,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004283305,"about_ca_topic_score_gemma":0.001663851,"domain_scores_codex":[0.9996935,0.0001311265,0.00002958991,0.00005847917,0.00004840226,0.00003899742],"domain_scores_gemma":[0.9996181,0.00008712173,0.00009851231,0.00002194462,0.00003869341,0.0001355676],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.4753128,0.02057694,0.03437308,0.002837697,0.003402612,0.0007072194,0.0003879606,0.001626383,0.09467738,0.0003765536,0.007780082,0.3579413],"study_design_scores_gemma":[0.2894054,0.5060124,0.1661842,0.0004144936,0.002228861,0.002404956,0.0003146917,0.004467526,0.01578266,0.0004293217,0.01224523,0.0001103206],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9928995,0.004271535,0.0001852986,0.0002619429,0.00006262663,0.0002609435,0.0003121981,0.00003980556,0.001706151],"genre_scores_gemma":[0.998076,0.0005737029,0.0002841673,0.0002490353,0.00003788593,0.0001581863,0.0002501388,0.00000355284,0.0003674651],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00198437,"threshold_uncertainty_score":0.006638348,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.002885365793110706,"score_gpt":0.2313277992595405,"score_spread":0.2284424334664298,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}